MX2021013317A - Combination therapies comprising apremilast and tyk2 inhibitors. - Google Patents

Combination therapies comprising apremilast and tyk2 inhibitors.

Info

Publication number
MX2021013317A
MX2021013317A MX2021013317A MX2021013317A MX2021013317A MX 2021013317 A MX2021013317 A MX 2021013317A MX 2021013317 A MX2021013317 A MX 2021013317A MX 2021013317 A MX2021013317 A MX 2021013317A MX 2021013317 A MX2021013317 A MX 2021013317A
Authority
MX
Mexico
Prior art keywords
apremilast
combination therapies
tyk2 inhibitors
tyk2
inhibitors
Prior art date
Application number
MX2021013317A
Other languages
Spanish (es)
Inventor
Peter Henry Schafer
Robert Plenge
Mary Adams
Lisa Beebe
Gilles Buchwalter
Tiffany Carr
Te-Chen Tzeng
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2021013317A publication Critical patent/MX2021013317A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Provided herein are methods of treating diseases and disorder responsive to the inhibition of PDE4 comprising administering apremilast and a Tyk2 inhibitor to a subject. Also provided herein are pharmaceutical compositions comprising apremilast and a Tyk2 inhibitor.
MX2021013317A 2019-04-30 2019-04-30 Combination therapies comprising apremilast and tyk2 inhibitors. MX2021013317A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/029772 WO2020222773A1 (en) 2019-04-30 2019-04-30 Combination therapies comprising apremilast and tyk2 inhibitors

Publications (1)

Publication Number Publication Date
MX2021013317A true MX2021013317A (en) 2022-01-18

Family

ID=66476870

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021013317A MX2021013317A (en) 2019-04-30 2019-04-30 Combination therapies comprising apremilast and tyk2 inhibitors.
MX2021013318A MX2021013318A (en) 2019-04-30 2020-04-30 Combination therapies comprising apremilast and tyk2 inhibitors.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021013318A MX2021013318A (en) 2019-04-30 2020-04-30 Combination therapies comprising apremilast and tyk2 inhibitors.

Country Status (14)

Country Link
EP (2) EP3962475A1 (en)
JP (2) JP2022537877A (en)
KR (2) KR20220002488A (en)
CN (2) CN114269336A (en)
AU (2) AU2019443366A1 (en)
BR (2) BR112021021809A2 (en)
CA (2) CA3138473A1 (en)
CL (1) CL2021002847A1 (en)
CO (2) CO2021015614A2 (en)
IL (2) IL287665A (en)
MA (1) MA55799A (en)
MX (2) MX2021013317A (en)
SG (2) SG11202112043PA (en)
WO (2) WO2020222773A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020222773A1 (en) 2019-04-30 2020-11-05 Celgene Corporation Combination therapies comprising apremilast and tyk2 inhibitors
IL305165A (en) 2021-02-19 2023-10-01 Sudo Biosciences Ltd Tyk2 inhibitors and uses thereof
WO2023049241A1 (en) * 2021-09-23 2023-03-30 Bristol-Myers Squibb Company Methods of treating hair-loss disorders with tyk2 inhibitors
WO2023076161A1 (en) 2021-10-25 2023-05-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
US8367689B2 (en) * 2009-05-06 2013-02-05 Portola Pharmaceuticals, Inc. Inhibitors of JAK
AU2011328237A1 (en) 2010-11-09 2013-05-23 Cellzome Limited Pyridine compounds and aza analogues thereof as TYK2 inhibitors
WO2012149251A1 (en) * 2011-04-28 2012-11-01 Celgene Corporation Methods and compositions using pde4 inhibitors for the treatment and management of autoimmune and inflammatory diseases
BR112014015923B1 (en) * 2011-12-27 2022-02-01 Amgen (Europe) GmbH TABLETS COATED WITH (+)-2-[1-(3-ETOXY-4-METOXY-PHENYL)-2-METHANE-SULPHONYLETHYL]-4 - ACETYLAMINOISOINDOLINE-1,3-DIONE
CN104159891B (en) 2012-01-10 2016-09-07 霍夫曼-拉罗奇有限公司 Pyridazine amide compound and they are as the purposes of SYK inhibitor
WO2013146963A1 (en) 2012-03-28 2013-10-03 武田薬品工業株式会社 Heterocyclic compound
CA2875990A1 (en) 2012-05-24 2013-11-28 Cellzome Limited Heterocyclyl pyrimidine analogues as tyk2 inhibitors
JP6407159B2 (en) 2012-11-08 2018-10-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and / or IFNα responses
AU2013341195B2 (en) 2012-11-08 2017-09-21 Bristol-Myers Squibb Company Alkyl amide-substituted pyrimidine compounds useful in the modulation of IL-12, IL-23 and/or IFNalpha
KR20150126618A (en) * 2013-03-14 2015-11-12 셀진 코포레이션 Treatment of psoriatic arthritis using apremilast
US20160159773A1 (en) 2013-07-30 2016-06-09 Takeda Pharmaceutical Company Limited Heterocyclic compound
RU2652795C2 (en) 2013-09-03 2018-05-03 Сареум Лимитед 2-phenyl-oxazole-4-carboxamide derivatives, modulating activity of jak and tyk2 kinase
TWI582077B (en) 2013-11-07 2017-05-11 必治妥美雅史谷比公司 Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnα responses
US10273237B2 (en) 2013-12-10 2019-04-30 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responses
WO2015091584A1 (en) 2013-12-18 2015-06-25 F. Hoffmann-La Roche Ag Thiazolopyridine compounds, compositions and their use as tyk2 kinase inhibitors
US9834548B2 (en) * 2014-02-14 2017-12-05 Portola Pharmaceuticals, Inc. Pyridazine compounds as JAK inhibitors
US9340540B2 (en) 2014-02-28 2016-05-17 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof
MX2016014384A (en) * 2014-06-23 2017-01-20 Celgene Corp Apremilast for the treatment of a liver disease or a liver function abnormality.
WO2016025686A1 (en) * 2014-08-15 2016-02-18 Celgene Corporation Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
NO2721710T3 (en) 2014-08-21 2018-03-31
WO2016047678A1 (en) 2014-09-25 2016-03-31 武田薬品工業株式会社 Heterocyclic compound
US20160251376A1 (en) 2015-02-27 2016-09-01 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
EP4327809A3 (en) 2015-09-02 2024-04-17 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
JP6505956B2 (en) 2016-02-24 2019-04-24 ファイザー・インク Pyrazolo [1,5-a] pyrazin-4-yl derivatives as JAK inhibitors
US10836770B2 (en) 2016-10-07 2020-11-17 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or INF alpha responses
TWI763722B (en) 2016-10-14 2022-05-11 美商林伯士拉克許米公司 Tyk2 inhibitors and uses thereof
AU2017345736B2 (en) 2016-10-21 2022-04-07 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
MA46620A (en) 2016-10-28 2021-05-26 Bristol Myers Squibb Co USEFUL HETEROBICYCLIC COMPOUNDS AS MODULATORS OF RESPONSES TO IL-12, IL-23 AND / OR IFN ALPHA
US11299494B2 (en) 2016-11-17 2022-04-12 Bristol-Myers Squibb Company Substituted imidazo[1,2-b]pyridazines as interleukin-23 and interferon-α modulators
GB2562702B (en) 2017-03-06 2022-05-18 Linear Shaped Ltd Frame and linear shaped charge
CA3055209A1 (en) * 2017-03-08 2018-09-13 Nimbus Lakshmi, Inc. Tyk2 inhibitors, uses, and methods for production thereof
WO2020222773A1 (en) 2019-04-30 2020-11-05 Celgene Corporation Combination therapies comprising apremilast and tyk2 inhibitors

Also Published As

Publication number Publication date
BR112021021826A8 (en) 2022-06-21
KR20220002488A (en) 2022-01-06
CO2021015614A2 (en) 2021-12-10
CA3138686A1 (en) 2020-11-05
MX2021013318A (en) 2022-01-31
AU2020266143A1 (en) 2021-12-02
AU2019443366A1 (en) 2021-12-02
SG11202112018YA (en) 2021-11-29
CO2021015622A2 (en) 2022-02-28
WO2020222773A1 (en) 2020-11-05
WO2020223431A1 (en) 2020-11-05
CA3138473A1 (en) 2020-11-05
SG11202112043PA (en) 2021-11-29
CN114269336A (en) 2022-04-01
EP3962476A1 (en) 2022-03-09
BR112021021826A2 (en) 2022-01-04
MA55799A (en) 2022-03-09
KR20220002489A (en) 2022-01-06
IL287665A (en) 2022-07-01
CL2021002847A1 (en) 2022-07-22
CN114206333A (en) 2022-03-18
JP2022537877A (en) 2022-08-31
JP2022537878A (en) 2022-08-31
EP3962475A1 (en) 2022-03-09
BR112021021809A2 (en) 2022-01-04
JP7453251B2 (en) 2024-03-19
IL287670A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
MX2021013318A (en) Combination therapies comprising apremilast and tyk2 inhibitors.
MX2022000711A (en) Parp1 inhibitors.
MX2021002804A (en) Combination therapies.
PH12019502132A1 (en) Combination therapy for the treatment or prevention of tumours
PH12018500097A1 (en) Combination of pd-1 antagonist with an egfr inhibitor
CR20210209A (en) 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
MX2018005600A (en) Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor.
PH12021551282A1 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
PH12020551425A1 (en) Rimegepant for cgrp related disorders
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
MX2022007376A (en) Fluoroalkyl-oxadiazoles and uses thereof.
MX2021002805A (en) Combination therapies.
WO2018208793A8 (en) S-nitrosoglutathione (gsno) and gsno reductase inhibitors for use in therapy
CR20220280A (en) Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor
MX2018008903A (en) COMPOSITIONS AND METHODS OF USE OF ß-HYDROXY-ß-METHYLBUTYRATE (HMB) FOR MODULATING AUTOPHAGY AND LIPOPHAGY.
MX2021007330A (en) Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor.
AR116024A1 (en) METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES
MX2020012782A (en) Ccr5 inhibitor for use in treating cancer.
WO2022261467A9 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
MX2020011912A (en) Combination therapy for treatment of hcv.
PH12021550671A1 (en) Prodrugs of cgrp antagonists
MX2020013805A (en) Pyridopyrimidinone derivatives for use as axl inhibitors.
CL2021002846A1 (en) Combination therapies comprising apremilast and tyk2 inhibitors
MX2018006631A (en) Compound for use in the prevention and treatment of neurodegenerative diseases.
MX2023002210A (en) Combination therapies with olig2 inhibitors.